Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs VICI Properties Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.9 (market cap $29.60B), while VICI Properties Inc trades at $26.07 (market cap $28.61B). The key difference: Alnylam Pharmaceuticals, Inc. and VICI Properties Inc are close in size by market cap, and VICI Properties Inc pays a 6.93% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VICI | |
|---|---|---|
Market Cap | $29.60B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $33.78 |
52-Week Low | $205.48 | $25.94 |
Enterprise Value | $27.56B | $46.16B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
VICI Properties trades at $26.03, down 0.17% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 67.5%, and a recent dividend of $0.45 paid in July 2026. Q2 2026 earnings saw an EPS miss at $0.48 versus $0.713 expected, though revenue beat forecasts, and the company raised its AFFO guidance.
Analyst consensus is strongly bullish with a $29.83 price target and 76.9% buy ratings, highlighting the 6.6% dividend yield and solid cash flow. Key risks include high debt levels, interest expense pressure, and uncertainty from the Caesars acquisition overhang, but the REIT's tangible assets and oligopoly advantages support long-term income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
